Base de dados : LILACS
Pesquisa : D09.698.373.200.300 [Categoria DeCS]
Referências encontradas : 54 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 54 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1285651
Autor: Medeiros, L H C; Vasconcelos, B M F; Silva, M B; Souza-Junior, A A; Chavante, S F; Andrade, G P V.
Título: Chondroitin sulfate from fish waste exhibits strong intracellular antioxidant potential
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;54(10):e10730, 2021. graf.
Idioma: en.
Projeto: CNPq.
Resumo: Chondroitin sulfate (CS) is a type of glycosaminoglycan described as an antioxidant molecule that has been found in animal species such as fish. Tilapia (Oreochromis niloticus) represents an eco-friendly source of this compound, since its economical processing generates usable waste, reducing the negative environmental impact. This waste was used for CS extraction, purification, characterization by enzymatic degradation, and evaluation of its antioxidant effect. CS obtained from tilapia presented sulfation mainly at carbon 4 of galactosamine, and it was not cytotoxic at concentrations up to 200 µg/mL. Furthermore, 100 µg/mL of CS from tilapia reduced the levels of reactive oxygen species to 47% of the total intracellular reactive oxygen species level. The ability of CS to chelate metal ions in vitro also suggested an ability to react with other pathways that generate oxidative radicals, such as the Haber-Weiss reaction, acting intracellularly in more than one way. Although the role of CS from tilapia remains unclear, the pharmacological effects described herein indicate that CS is a potential molecule for further study of the relationship between the structures and functions of chondroitin sulfates as antioxidants.
Descritores: Sulfatos de Condroitina
Antioxidantes/farmacologia
-Espécies Reativas de Oxigênio
Peixes
Glicosaminoglicanos
Limites: Animais
Responsável: BR1.1 - BIREME


  2 / 54 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-840799
Autor: Tutolo, Manuela; Ammirati, Enrico; Castagna, Giulia; Klockaerts, Katrien; Plancke, Hendrik; Ost, Dieter; Aa, Frank Van der; Ridder, Dirk De.
Título: A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroïtin sulphate 2% for painful bladder syndrome/interstitial cystitis
Fonte: Int. braz. j. urol;43(1):134-141, Jan.-Feb. 2017. tab.
Idioma: en.
Resumo: ABSTRACT Objective To compare effectiveness of intravesical chondroïtin sulphate (CS) 2% and dimethyl sulphoxide (DMSO) 50% in patients with painful bladder syndrome/interstitial cystitis (PBS/IC). Materials and methods Patients were randomized to receive either 6 weekly instillations of CS 2% or 50% DMSO. Primary endpoint was difference in proportion of patients achieving score 6 (moderately improved) or 7 (markedly improved) in both groups using the Global Response Assessment (GRA) scale. Secondary parameters were mean 24-hours frequency and nocturia on a 3-day micturition dairy, changes from baseline in O’Leary-Sant questionnaire score and visual analog scale (VAS) for suprapubic pain. Results Thirty-six patients were the intention to treat population (22 in CS and 14 in DMSO group). In DMSO group, 57% withdrew consent and only 6 concluded the trial. Major reasons were pain during and after instillation, intolerable garlic odor and lack of efficacy. In CS group, 27% withdrew consent. Compared with DMSO group, more patients in CS group (72.7% vs. 14%) reported moderate or marked improvement (P=0.002, 95% CI 0.05-0.72) and achieved a reduction in VAS scores (20% vs. 8.3%). CS group performed significantly better in pain reduction (-1.2 vs. -0.6) and nocturia (-2.4 vs. -0.7) and better in total O’Leary reduction (-9.8 vs. -7.2). CS was better tolerated. The trial was stopped due to high number of drop-outs with DMSO. Conclusions Intravesical CS 2% is viable treatment for PBS/IC with minimal side effects. DMSO should be used with caution and with active monitoring of side effects. More randomized controlled studies on intravesical treatments are needed.
Descritores: Dimetil Sulfóxido/administração & dosagem
Sulfatos de Condroitina/administração & dosagem
Cistite Intersticial/tratamento farmacológico
-Fatores de Tempo
Micção
Administração Intravesical
Medição da Dor
Estudos Prospectivos
Inquéritos e Questionários
Reprodutibilidade dos Testes
Resultado do Tratamento
Agentes Urológicos/administração & dosagem
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Idoso
Adulto Jovem
Responsável: BR1.1 - BIREME


  3 / 54 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975664
Autor: Silva, Matheus N. Ribeiro da; Mendes, Aline; Martins, João R. Maciel; Tobias-Machado, Marcos; Pinhal, Maria Aparecida da Silva.
Título: Prospective evaluation of Chondroitin sulfate, Heparan sulfate and Hyaluronic acid in prostate cancer
Fonte: Int. braz. j. urol;44(6):1139-1146, Nov.-Dec. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: The present study evaluates chondroitin sulfate (CS) and heparan sulfate (HS) in the urine and hyaluronic acid (HA) in the plasma of patients with prostate cancer before and after treatment compared to a control group. Materials and Methods: Plasma samples were used for HA dosage and urine for quantification of CS and HS from forty-four cancer patients and fourteen controls. Clinical, laboratory and radiological information were correlated with glycosaminoglycan quantification by statistical analysis. Results: Serum HA was significantly increased in cancer patients (39.68 ± 30.00 ng/ mL) compared to control group (15.04 ± 7.11 ng/mL; p=0.004) and was further increased in high-risk prostate cancer patients when compared to lower risk patients (p = 0.0214). Also, surgically treated individuals had a significant decrease in seric levels of heparan sulfate after surgical treatment, 31.05 ± 21.01 μg/mL (before surgery) and 23.14 ± 11.1 μg/mL (after surgery; p=0.029). There was no difference in the urinary CS and HS between prostate cancer patients and control group. Urinary CS in cancer patients was 27.32 ± 25.99 μg/mg creatinine while in the men unaffected by cancer it was 31.37 ± 28.37 μg/mg creatinine (p=0.4768). Urinary HS was 39.58 ± 32.81 μg/ mg creatinine and 35.29 ± 28.11 μg/mg creatinine, respectively, in cancer patients and control group (p=0.6252). Conclusions: Serum HA may be a useful biomarker for the diagnosis and prognosis of prostate cancer. However, urinary CS and HS did not altered in the present evaluation. Further studies are necessary to confirm these preliminary findings.
Descritores: Neoplasias da Próstata/urina
Neoplasias da Próstata/sangue
Sulfatos de Condroitina/urina
Heparitina Sulfato/urina
Ácido Hialurônico/sangue
-Biomarcadores Tumorais/urina
Biomarcadores Tumorais/sangue
Estudos de Casos e Controles
Estudos Prospectivos
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Idoso
Responsável: BR1.1 - BIREME


  4 / 54 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1001822
Autor: Coimbra, Ibsen Bellini; Plapler, Pérola Grinberg; Campos, Gustavo Constantino de.
Título: Generating evidence and understanding the treatment of osteoarthritis in Brazil: a study through Delphi methodology
Fonte: Clinics;74:e722, 2019. tab, graf.
Idioma: en.
Resumo: OBJECTIVES: This study aimed to provide evidence for understanding how to treat osteoarthritis (OA) in our country. Therefore, it was necessary to match information and investigations related to the treatment of the disease from the three main types of specialists involved: physiatrists, orthopedists and rheumatologists. METHODS: The authors acted as a scientific advisory committee. From the initial discussions, a structured questionnaire was developed for use with a group of specialists on OA using the Delphi technique. The questionnaire was sent to 21 experts appointed by the authors, and the results obtained were critically analyzed and validated. RESULTS: The prevalence of OA was 33% in Brazil, corresponding to one-third of the individuals in the reference population, which included individuals over 25 years of age. Another significant finding was that most patients did not receive any form of treatment in the early stages of OA. CONCLUSION: The committee pointed to the need for early intervention and that the available medicinal resources can fulfil this important role, as is the case with SYSADOA treatments. Glucosamine-based medicinal products with or without chondroitin could also fulfill this need for early treatment. The other generated evidence and included investigations were then grouped together and are the subject of this publication.
Descritores: Osteoartrite/terapia
Técnica Delfos
Competência Clínica/normas
Medicina Baseada em Evidências/normas
-Ortopedia/normas
Osteoartrite/tratamento farmacológico
Medicina Física e Reabilitação/normas
Índice de Gravidade de Doença
Brasil
Anti-Inflamatórios não Esteroides/administração & dosagem
Sulfatos de Condroitina/uso terapêutico
Resultado do Tratamento
Osteoartrite do Joelho/terapia
Consenso
Quimioterapia Combinada
Glucosamina/uso terapêutico
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  5 / 54 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1003065
Autor: Almeida, Fernando Gonçalves de; Batezini, Nelson Sivonei da Silva; Simões, Ricardo Santos; Bernardo, Wanderley M.
Título: Interstitial cystitis - intravesical treatment
Fonte: Rev. Assoc. Med. Bras. (1992);65(4):535-540, Apr. 2019.
Idioma: en.
Resumo: The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.
Descritores: Cistite Intersticial/tratamento farmacológico
-Poliéster Sulfúrico de Pentosana/uso terapêutico
Administração Intravesical
Brasil
Dimetil Sulfóxido/uso terapêutico
Sulfatos de Condroitina/uso terapêutico
Resultado do Tratamento
Toxinas Botulínicas Tipo A/uso terapêutico
Diterpenos/uso terapêutico
Tomada de Decisão Clínica
Ácido Hialurônico/uso terapêutico
Lidocaína/uso terapêutico
Mycobacterium bovis
Limites: Humanos
Tipo de Publ: Guia de Prática Clínica
Revisão Sistemática
Responsável: BR1.1 - BIREME


  6 / 54 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1122775
Autor: Maglione, Horacio O; Luberti, Ricardo Felipe.
Título: Consideraciones clínicas e imagenológicas de la osteoartrosis en la articulación temporomandibular / Clinical and imaging remarks on temporomandibular joint osteoarthrosis
Fonte: Rev. Círc. Argent. Odontol;77(227):13-17, dic. 2018. ilus, tab.
Idioma: es.
Resumo: La osteoartrosis es una enfermedad degenerativa que, instalada en la articulación temporomandibular, genera efectos deletéreos en los tejidos blandos y óseos que la constituyen. En los tejidos duros se destaca la aparición de procesos osteolíticos a nivel condilar y de la cavidad glenoidea con cambios morfológicos importantes. Estas modificaciones están íntimamente relacionadas con el debilitamiento y/o destrucción de los tejidos blandos que ocurren previamente. Los síntomas que se presentan con mayor frecuencia en esta afección son la alteración del rango de movimiento, el dolor y, el más característico, la crepitación durante el examen con estetoscopio. La frecuencia de aparición alcanza entre un 8% y un 18%. Las causas para su documentación son variables y están vinculadas al desplazamiento discal, el trauma, hormonales y la inestabilidad oclusal, siendo el aumento de carga (bruxismo) la de mayor significación. El examen imagenológico puede documentar aplanamiento de los componentes óseos, disminución del espacio articular, discontinuidad de las corticales, esclerosis subcondral, osteofitos, quistes subcondrales y cuerpos libres periarticulares. En ocasiones la radiografía panorámica puede ser poco demostrativa para la documentación de esas particularidades; por el contrario, la tomografía computada es un excelente procedimiento diagnóstico. El aporte de la IRM es relevante en la ubicación del disco articular; asimismo, posibilita la observación de colección de fluido en los espacios articulares, generando una señal hiperintensa. Tratamiento: actuar principalmente para disminuir la carga sobre la ATM y,`por lo tanto, concientizar al paciente de la presencia del bruxismo, instalar un dispositivo oclusal miorrelajante (DOM) y suplementar con analgésicos, antiinflamatorios y antiartrósicos. Cuando la OA está asociada al desplazamiento discal, debe indicarse un dispositivo oclusal de desplazamiento anterior mandibular (DODAM) (AU)

Osteoarthrosis is a degenerative disease. When is located in the TMJ produces deleterious effects in its soft and hard tissues, osteolytic processes on condyle and glenoid cavity in the latter, with significant morphological changes, closely related to weakening and destruction of the tissues that had happened previously. Symptoms most frequent are alteration of the range of movement, pain and,the most characterystic, cracking while examination through stethoscope. Its frequency is between 8 and 18%.Causes for its documentation are variable and related to disc displacement, trauma, hormones and occlusal unsteadiness, being de increase of charge (clenching) the most relevant. Imaging can show flattening on osseusparts,, the articular space, discontinuation of cortexes, subchondral sclerosis, osteophytes, subchondral cysts,and loose particular bodies. Sometimes orthopantomograph may be barely demonstrative to document these phenomena, conversely CT is an excellent diagnostic procedure. The contribution of MRI is relevant to locate articular disc, and facilitate visualize fluid collection within the articular spaces, producing a hiperintense signal. Treatment: to act mainly for diminishing charge on the TMJ, so to raise patients conscience of the presence of clenching, install a myorelaxant occlusal device (DOM) and additionally analgesics, antiinflamatories and antiarthrosis When osteoarthrosis is associated with disc displacement and occlusal device for anterior mandibular displacement (DODAM) is suitable(AU)
Descritores: Osteoartrite/patologia
Transtornos da Articulação Temporomandibular/diagnóstico por imagem
-Osteoartrite/tratamento farmacológico
Sinais e Sintomas
Bruxismo
Imageamento por Ressonância Magnética
Radiografia Panorâmica
Tomógrafos Computadorizados
Doença Crônica
Sulfatos de Condroitina/uso terapêutico
Placas Oclusais
Distribuição por Idade e Sexo
Analgésicos/uso terapêutico
Anti-Inflamatórios
Limites: Humanos
Masculino
Feminino
Responsável: AR29.1 - Biblioteca


  7 / 54 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-735432
Autor: Castañeda, Oswaldo; Kuroiwa, Rita; Torres, David; Castañeda, Alejandra; Manche-Kuroiwa, Sandra; Priori, Ennio.
Título: Evaluación de la eficacia y seguridad del ácido hialurónico por vía oral asociado con glucosamina sulfato, condroitín sulfato y metilsulfonilmetano comparado con la asociación por vía oral de glucosamina sulfato, condroitín sulfato y metilsulfonilmetano en la osteoartritis de rodilla / Evaluation of the efficacy and safety of the orally association of hyaluronic acid, glucosamine sulfate, chondroitin sulfate and methylsulfonylmethane compared with the association of glucosamine sulfate, chondroitin sulfate and methylsulfonylmethane in knee osteoarthritis
Fonte: Acta méd. peru;31(3):157-164, jul.-set. 2014. ilus, tab.
Idioma: es.
Resumo: Objetivo. Comparar la eficacia y la seguridad de la asociación de ácido hialurónico (AH), glucosamina sulfato (GS), condroitina sulfato (CS) y metilsulfonilmetano (MSM) versus GS, CS y MSM en el control de los síntomas de la osteoartritis (OA) de rodilla. Material y Método. Estudio comparativo, aleatorizado prospectivo, a doble ciego, en pacientes con OA de rodilla, divididos en dos grupos, durante tres meses de tratamiento diario, vía oral. El grupo 1 recibió AH 120 mg + GS 1 500 mg + CS 1 200 mg + MSM 1 000 mg y el grupo 2, la misma asociación pero sin AH. Se incluyeron hombres y mujeres mayores de 40 años y menores de 80 años con diagnóstico de OA de rodilla, según el criterio modificado del Colegio Americano Reumatología (ACR). Se realizaron cuatro evaluaciones, inicial y a las 4, 8 y 12 semanas de tratamiento. El dolor se evalúo con la escala de WOMAC 3.1 y la escala visual análoga (EVA) y el estado de salud, con el cuestionario SF-36 versión 2. En todas las visitas se proporcionó al paciente un formulario para que anote la presencia de algún evento adverso. Resultados. Los grupos 1 y 2 tuvieron similares datos en edad, género, grado de instrucción y tiempo de enfermedad, sin diferencia estadística significativa. Todos los pacientes cumplieron con los criterios del ACR. El grupo 1 tuvo mejores puntajes con diferencia estadísticamente significativa en la variable EVA entre todos los grupos en la semana 12 y en la variable SF-36 en la semana 12. Conclusiones. Se puede concluir que la asociación GS-CS-MSM-AH por vía oral sería más eficaz y de igual seguridad que la asociación GS-CS-MSM en el control de los síntomas de la OA de rodilla.

Objective. To compare the efficacy and safety of the orally combination of hyaluronic acid (HA), glucosamine sulfate (GS), chondroitin sulfate (CS) and methylsulfonylmethane (MSM) versus GS, CS and MSM for controlling the symptoms of osteoarthritis (OA) knee. Material and Methods. Prospective randomized, double-blind, comparative study, in patients with knee OA were divided into two groups for three months of daily treatment, orally. Group 1 received HA 120 mg + GS 1500 mg + CS 1200 mg + MSM 1000 mg, and group 2, the same association but without HA. Men and women aged 40 years and under 80 years diagnosed with knee OA were included, according to the modified criteria of the American College of Rheumatology (ACR). Four evaluations, initial and at 4, 8 and 12 weeks of treatment were made. Pain was assessed with the WOMAC 3.1 scale and visual analogue scale (VAS) and health status with the SF-36 version 2 questionnaire. In all patient visits provided a form to record the presence of any adverse events. Results. Groups 1 and 2 were similar in age, gender, level of education and sick time, without statistically significant differences. All patients fulfilled the ACR criteria. Group 1 had better scores with statistically significant difference in VAS variable among all groups at week 12 and the SF-36 variable in week 12. Conclusions. It can be concluded that HA-GS-CS-MSM orally association would be more effective and equally safety that GS-CS-MSM association in controlling the symptoms of knee OA.
Descritores: Osteoartrite do Joelho
Sulfatos de Condroitina/uso terapêutico
Ácido Hialurônico/uso terapêutico
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Responsável: PE1.1 - Oficina Universitária de Biblioteca


  8 / 54 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-508002
Autor: Anon.
Título: Glucosamida e condroitina: efetivas para o tratamento da osteoartrose / Glucosamine and Chondroitin: effective for the treatment of osteoarthritis
Fonte: Diagn. tratamento;9(3):138-138, jul.-set. 2004.
Idioma: pt.
Descritores: Osteoartrite/terapia
Sulfatos de Condroitina/uso terapêutico
Responsável: BR12.1 - Biblioteca Setorial da Ciências da Saúde


  9 / 54 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Borges, A. P. B
Texto completo
Texto completo
Id: lil-747063
Autor: Eleotério, R. B; Pontes, K. C. S; Machado, J. P; Reis, E. C. C; Ferreira, P. S; Silva, M. B; Martins, N. J. S; Fernandes, N. A; Borges, A. P. B.
Título: Chondroitin sulfate and glucosamine in the cartilage and subchondral bone repair of dogs - Histological findings / Sulfato de condroitina e glucosamina na reparação da cartilagem e do osso subcondral de cães - Achados histológicos
Fonte: Arq. bras. med. vet. zootec;67(2):325-333, Mar-Apr/2015. tab, ilus.
Idioma: en.
Resumo: Chondroitin and glucosamine sulfate nutraceuticals are commonly used in the management of degenerative articular disease in veterinary routine. However, there are controversies on the contribution of these substances to articular cartilage. The purpose of this study was to evaluate the efficiency of a chondroitin and glucosamine sulfate-based veterinary nutraceutical on the repair of an induced osteochondral defect in a dog femoral condyle, by macroscopic, histological and histomorphometric analyses. The nutraceutical was orally administered the day following injury induction, every 24 hours (treated group, TG, n=24), compared with animals that did not receive the product (control group, CG, n=24). Six animals per group were anaesthetized for sample collection at 15, 30, 60 and 90 days after surgery. At 15 days, defects were macroscopically filled with red-pinkish tissue. After 30 days, whitish color tissue was observed, both in TG and CG animals, with firmer consistency to touch at 60 and 90 postoperative days. Histological analysis demonstrated that, in both groups, there was initial blood clot formation, which was subsequently substituted by a fibrin net, with capillary proliferation from the adjacent bone marrow and infiltration of mesenchymal cells in clot periphery. As cellular differentiation developed, repair tissue presented a fibrocartilage aspect most of the time, and new subchondral bone formation occurred in the deepest area corresponding to the defect. Histomorphometry suggested that the nutraceutical did not favor the articular cartilage repair process. It was concluded that nutraceutical did not significantly influence chondrocytes proliferation or hyaline architecture restoration.(AU)

Os nutracêuticos compostos de sulfato de condroitina e glucosamina são comumente utilizados no manejo da doença articular degenerativa na rotina veterinária. Entretanto, existem controvérsias sobre a contribuição dessas substâncias à cartilagem articular. O objetivo deste trabalho foi avaliar a eficácia de um nutracêutico veterinário à base de sulfato de condroitina e glucosamina na reparação de defeitos osteocondrais induzidos no côndilo femoral de cães, através de análises macroscópica, histológica e histomorfométrica. O nutracêutico foi administrado no dia seguinte à indução da lesão, pela via oral, a cada 24 horas (grupo tratado - GT, 24 animais), sendo comparado a animais que não receberam o produto (grupo controle - GC, de igual número de animais). Aos 15, 30, 60 e 90 dias após a cirurgia, seis animais por grupo foram anestesiados para ser realizada a coleta das amostras. Aos 15 dias, os defeitos eram macroscopicamente preenchidos por tecido de coloração rósea a avermelhada. Já a partir dos 30 dias, observou-se preenchimento por tecido de coloração esbranquiçada, tanto nos animais do GT quanto nos do GC, com consistência mais firme ao toque digital aos 60 e 90 dias de pós-operatório. A análise histológica revelou que, em ambos os grupos, houve inicialmente formação de coágulo sanguíneo que, posteriormente, foi substituído por uma rede de fibrina, com proliferação de capilares a partir da medula óssea adjacente e infiltração de células mesenquimais na periferia do coágulo. À medida que se processou a diferenciação celular, o tecido de reparação se apresentou na maioria das vezes com aspecto de fibrocartilagem e, na região mais profunda da área correspondente ao defeito, ocorreu formação de osso novo subcondral. A histomorfometria sugeriu que o nutracêutico não favoreceu o processo de reparação da cartilagem articular. Concluiu-se que o nutracêutico não influenciou consideravelmente na proliferação de condrócitos nem na restauração da arquitetura hialina.(AU)
Descritores: Osteoartrite/veterinária
Doenças das Cartilagens/veterinária
Sulfatos de Condroitina/uso terapêutico
Artroplastia Subcondral/veterinária
Glucosamina/uso terapêutico
Artropatias/veterinária
Limites: Animais
Cães
Responsável: BR68.1 - Biblioteca Virginie Buff D'Ápice


  10 / 54 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-951891
Autor: Reis, Camila Borges dos; Boff, Daniele Schaab; Lima, Isabela Angeli de; Santos, Leandro Freire dos; Calvalcanti, Osvaldo Albuquerque; Bunhak, Élcio José.
Título: Eudragit ® FS 30 D polymeric films containing chondroitin sulfate as candidates for use in coating seeking modified delivery of drugs
Fonte: Braz. j. pharm. sci;52(4):635-643, Oct.-Dec. 2016. graf.
Idioma: en.
Resumo: ABSTRACT Polymeric films associating different concentrations of Eudragit(r) FS 30 D (EFS) and chondroitin sulfate (CS) were produced by casting for the development of a new target-specific site material. Formed films kept a final polymer mass of 4% (w/v) in the following proportions: EFS 100:00 CS (control), EFS 95:05 CS, EFS 90:10 CS and EFS 80:20 CS. They were analyzed for physical and chemical characteristics using Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM) and Raman spectroscopy. Furthermore, they were characterized by their water vapor permeability and degree of hydration at different conditions simulating the gastrointestinal tract. No chemical interactions were observed between CS and EFS, suggesting only a physical interaction between them in the different combinations tested. The results suggest that EFS and CS, when combined, may form films that are candidates for coating processes seeking a modified drug delivery, especially due to the synergism between pH dependency and specific biodegradability properties by the colonic microbiota. EFS 90:10 CS proved to be the most suitable for this purpose considering hydration and permeability characteristics of different associations analyzed.
Descritores: Polímeros/efeitos adversos
Sulfatos de Condroitina/análise
Revestimentos/classificação
-Análise Espectral Raman/instrumentação
Microscopia Eletrônica de Varredura/instrumentação
Administração Oral
Espectroscopia de Infravermelho com Transformada de Fourier/instrumentação
Liberação Controlada de Fármacos
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde